Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...

Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...

And as targeting technology improves, large pharma companies are paying closer attention to the drug field and the many smaller biotechnology firms within ... chemistry and biomarker technology to ...

Image Source: Getty Images ... This yield slightly exceeds the average of 3.12% among its big pharma and blue-chip biotech peers. The company's five-year dividend growth rate of 6.1% compares ...

CG Oncology remains the biggest IPO winner this year, having raised $380m in January. Image credit: Shutterstock / JHVEPhoto. Bicara Therapeutics has raised $362m in gross proceeds from its initial ...

The fall flurry of biotech IPOs shows no signs of abating, with Upstream Bio becoming the latest company to express an intention to go public. The Waltham, Massachusetts-based biotech has yet to ...

For decades, the biotech company Genentech has carved out a reputation in the industry as a scientist’s paradise, a place ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on IO Biotech (IOBT – Research Report). The associated price target remains the same with $12.00. Emily Bodnar has given ...

So, he truly has skin in the game,” GCTx co-founder and Chief Scientific Officer Alex Ng, Ph.D., told Fierce Biotech. “Along with this deep contribution, we're really proud to have his ...

NKGen Biotech, Inc., a biotechnology company specializing in biological products, announced today that it will appeal the Nasdaq's decision to delist its common stock from the Nasdaq Global Market.